Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) - Total Liabilities
Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has total liabilities worth CN¥8.99 Billion CNY (≈ $1.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Total Liabilities Trend (1994–2025)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's total liabilities have evolved over time, based on quarterly financial data. See Starlake Bioscience Co Inc Zhaoqing Guan (600866) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Total Liabilities
The table below lists competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Preferred Bank
NASDAQ:PFBC
|
USA | $6.88 Billion |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
India | Rs60.62 Billion |
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
China | CN¥5.84 Billion |
|
OVH GROUPE UNSP.ADR/1/2
F:7U70
|
Germany | €1.67 Billion |
|
Faraday Copper Corp.
TO:FDY
|
Canada | CA$15.27 Million |
|
Usinas Siderúrgicas de Minas Gerais S.A
SA:USIM3
|
Brazil | R$12.46 Billion |
|
Ho Chi Minh City Securities Corp
VN:HCM
|
Vietnam | ₫31.96 Trillion |
|
Zhejiang Grandwall Electric Science&Technology Co Ltd Class A
SHG:603897
|
China | CN¥4.23 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Starlake Bioscience Co Inc Zhaoqing Guangdong's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Starlake Bioscience Co Inc Zhaoqing Guan market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Starlake Bioscience Co Inc Zhaoqing Guangdong's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2025)
The table below shows the annual total liabilities of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥8.79 Billion ≈ $1.29 Billion |
+34.83% |
| 2024-12-31 | CN¥6.52 Billion ≈ $953.84 Million |
-3.08% |
| 2023-12-31 | CN¥6.73 Billion ≈ $984.11 Million |
-25.85% |
| 2022-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
+1199.80% |
| 2021-12-31 | CN¥697.74 Million ≈ $102.10 Million |
-7.34% |
| 2020-12-31 | CN¥752.97 Million ≈ $110.18 Million |
+26.35% |
| 2019-12-31 | CN¥595.95 Million ≈ $87.21 Million |
+21.89% |
| 2018-12-31 | CN¥488.94 Million ≈ $71.55 Million |
-8.54% |
| 2017-12-31 | CN¥534.57 Million ≈ $78.22 Million |
-16.20% |
| 2016-12-31 | CN¥637.90 Million ≈ $93.35 Million |
-19.85% |
| 2015-12-31 | CN¥795.88 Million ≈ $116.46 Million |
+1.08% |
| 2014-12-31 | CN¥787.37 Million ≈ $115.22 Million |
-30.83% |
| 2013-12-31 | CN¥1.14 Billion ≈ $166.57 Million |
-32.96% |
| 2012-12-31 | CN¥1.70 Billion ≈ $248.48 Million |
+4.80% |
| 2011-12-31 | CN¥1.62 Billion ≈ $237.09 Million |
+132.10% |
| 2010-12-31 | CN¥698.07 Million ≈ $102.15 Million |
+46.24% |
| 2009-12-31 | CN¥477.36 Million ≈ $69.85 Million |
-17.76% |
| 2008-12-31 | CN¥580.44 Million ≈ $84.94 Million |
-4.42% |
| 2007-12-31 | CN¥607.29 Million ≈ $88.87 Million |
+17.49% |
| 2006-12-31 | CN¥516.89 Million ≈ $75.64 Million |
+5.58% |
| 2005-12-31 | CN¥489.57 Million ≈ $71.64 Million |
+19.16% |
| 2004-12-31 | CN¥410.86 Million ≈ $60.12 Million |
+53.99% |
| 2003-12-31 | CN¥266.82 Million ≈ $39.04 Million |
+41.26% |
| 2002-12-31 | CN¥188.89 Million ≈ $27.64 Million |
-23.21% |
| 2001-12-31 | CN¥245.97 Million ≈ $35.99 Million |
-25.81% |
| 2000-12-31 | CN¥331.53 Million ≈ $48.51 Million |
+130.43% |
| 1999-12-31 | CN¥143.87 Million ≈ $21.05 Million |
-13.09% |
| 1998-12-31 | CN¥165.54 Million ≈ $24.22 Million |
+53.52% |
| 1997-12-31 | CN¥107.83 Million ≈ $15.78 Million |
-37.62% |
| 1996-12-31 | CN¥172.86 Million ≈ $25.30 Million |
-7.81% |
| 1995-12-31 | CN¥187.51 Million ≈ $27.44 Million |
+21.64% |
| 1994-12-31 | CN¥154.15 Million ≈ $22.56 Million |
-- |
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more